Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2013
When drugs fail, sometimes it’s not because they don’t work — it’s because they were tested on the wrong population. Auransa’s hypothesis-free machine learning algorithms sort through RNA transcriptome data to find patients with molecular subtypes of diseases that might respond better to known drug compounds. It offers its technology to partners and is developing its own pipeline of novel drugs for liver cancer and other conditions.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules